The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
Official Title: A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Study ID: NCT02205333
Brief Summary: The main purpose of this study is to determine the best dose of MEDI6469 that is safe and tolerable when given as monotherapy and in combination with tremelimumab, MEDI4736 (durvalumab), or rituximab in participants with either advanced solid tumors or diffuse large B-cell lymphoma (DLBCL). Tremelimumab and MEDI4736 (durvalumab) will be tested with MEDI6469 in a set of participants with advanced solid tumors while rituximab will be tested with MEDI6469 in participants with DLBCL. MEDI6469 will be tested as monotherapy in participants with advanced solid tumors.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Research Site, Scottsdale, Arizona, United States
Research Site, Sacramento, California, United States
Research Site, Santa Monica, California, United States
Research Site, Washington, D.C., District of Columbia, United States
Research Site, Tampa, Florida, United States
Research Site, Chicago, Illinois, United States
Research Site, Detroit, Michigan, United States
Research Site, Las Vegas, Nevada, United States
Research Site, Hackensack, New Jersey, United States
Research Site, Huntersville, North Carolina, United States
Research Site, Portland, Oregon, United States
Research Site, Memphis, Tennessee, United States
Research Site, Houston, Texas, United States
Name: MedImmune, LLC
Affiliation: MedImmune LLC
Role: STUDY_DIRECTOR